ES2245944T3 - Uso de composiciones para tratar o prevenir alteraciones del sueño utilizando dosis muy bajas de ciclobenzaprina. - Google Patents

Uso de composiciones para tratar o prevenir alteraciones del sueño utilizando dosis muy bajas de ciclobenzaprina.

Info

Publication number
ES2245944T3
ES2245944T3 ES00953996T ES00953996T ES2245944T3 ES 2245944 T3 ES2245944 T3 ES 2245944T3 ES 00953996 T ES00953996 T ES 00953996T ES 00953996 T ES00953996 T ES 00953996T ES 2245944 T3 ES2245944 T3 ES 2245944T3
Authority
ES
Spain
Prior art keywords
dose
compositions
treat
low dose
cycllobenzaprine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00953996T
Other languages
English (en)
Inventor
Iredell W Iglehart Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Pharmaceuticals Inc
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2245944T3 publication Critical patent/ES2245944T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos y composiciones que comprenden una dosis muy baja de ciclobenzaprina o un metabolito de la misma para prevenir y tratar alteraciones del sueño y enfermedades que se manifiestan con una disfunción del sueño, incluyendo síndrome de fibromialgia, síndrome de fatiga crónica, trastornos del sueño, trastornos del dolor psicogénico, o síndromes de dolor crónico, o síntomas de las mismas. La presente invención se refiere, además, a métodos y composiciones pra tratar alteraciones del sueño, dolor crónico o fatiga en humanos que sufren de síndrome de fibromialgia, síndrome de fatiga crónica, trastornos del sueño, trastornos de dolor psicogénico, síndromes de dolor crónico, usando una dosis muy baja de ciclobenzaprina.
ES00953996T 1999-08-13 2000-08-11 Uso de composiciones para tratar o prevenir alteraciones del sueño utilizando dosis muy bajas de ciclobenzaprina. Expired - Lifetime ES2245944T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14888199P 1999-08-13 1999-08-13

Publications (1)

Publication Number Publication Date
ES2245944T3 true ES2245944T3 (es) 2006-02-01

Family

ID=22527835

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200250016A Withdrawn - After Issue ES2192156B1 (es) 1999-08-13 2000-08-11 Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina.
ES00953996T Expired - Lifetime ES2245944T3 (es) 1999-08-13 2000-08-11 Uso de composiciones para tratar o prevenir alteraciones del sueño utilizando dosis muy bajas de ciclobenzaprina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200250016A Withdrawn - After Issue ES2192156B1 (es) 1999-08-13 2000-08-11 Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina.

Country Status (18)

Country Link
US (3) US6395788B1 (es)
EP (1) EP1202722B1 (es)
JP (1) JP2003506484A (es)
AR (1) AR025110A1 (es)
AT (1) ATE299369T1 (es)
AU (1) AU6635400A (es)
BR (1) BR0013017A (es)
CA (1) CA2380432A1 (es)
DE (1) DE60021266T2 (es)
ES (2) ES2192156B1 (es)
GB (1) GB2368522A (es)
HK (2) HK1047883A1 (es)
IL (1) IL147777A0 (es)
MX (1) MXPA02001569A (es)
NZ (1) NZ516749A (es)
PT (1) PT1202722E (es)
WO (1) WO2001012175A1 (es)
ZA (2) ZA200200619B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
JP4578083B2 (ja) * 2003-09-30 2010-11-10 小林製薬株式会社 催眠剤組成物
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
DK1954669T3 (en) 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
WO2007098202A2 (en) 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid based apparatus, system, and method for therapeutic treatment of a patient
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
EP3103790B1 (en) 2007-03-15 2018-05-09 Auspex Pharmaceuticals, Inc. Substituted phenethylamine with serotoninergic and/or norepinephrinergic activity
US20100198103A1 (en) 2007-10-09 2010-08-05 Imthera Medical, Inc. System and method for neural stimulation
CA2730190A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
BR112012010986A2 (pt) 2009-11-10 2016-04-12 Imthera Medical Inc sistema para estimular um nervo hipoglosso para o controle da posição da língua de um paciente
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US20120232159A1 (en) * 2011-03-07 2012-09-13 Tonix Pharmaceuticals, Inc. Methods and Compositions for Treating Depression using Cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
US9346742B2 (en) * 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
AU2013274003B2 (en) 2012-06-15 2018-07-05 Tonix Pharma Holdings Limited Compositions and methods for transmucosal absorption
SG10201707528WA (en) 2013-03-15 2017-10-30 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
SG11201701995PA (en) 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
JP2020526592A (ja) 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション シクロベンザプリン類似体及びアミトリプチレン類似体
EP3723860A1 (en) 2017-12-11 2020-10-21 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
CN113194935A (zh) * 2018-08-20 2021-07-30 通尼克斯制药控股有限公司 治疗急性应激障碍和创伤后应激障碍的方法
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CN115803088A (zh) * 2020-04-08 2023-03-14 通尼克斯医药控股公司 性功能障碍的环苯扎林治疗
CN116887830A (zh) 2020-11-20 2023-10-13 通尼克斯医药控股公司 酒精使用障碍的环苯扎林治疗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339636A (en) * 1917-02-23 1920-05-11 Tulloch Thomas Gregorie Fluid-tight joint for steam-pipes and the like
GB859187A (en) 1958-11-25 1961-01-18 United States Borax Chem Method for preparing substituted tris amino boranes
CA958643A (en) 1970-07-07 1974-12-03 Frosst (Charles E.) And Co. Pharmaceutical compositions containing cyclobenzaprine
FR2121529A1 (en) * 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid
JP2003506483A (ja) * 1999-08-13 2003-02-18 ベラ・ファーマシューティカルズ・インコーポレイテッド シクロベンザプリンおよびその組成物による全般性不安障害の処置

Also Published As

Publication number Publication date
BR0013017A (pt) 2002-04-16
HK1047883A1 (zh) 2003-03-14
US6541523B2 (en) 2003-04-01
PT1202722E (pt) 2005-11-30
ES2192156A1 (es) 2003-09-16
DE60021266T2 (de) 2006-05-24
AR025110A1 (es) 2002-11-06
ZA200200619B (en) 2003-04-23
EP1202722A1 (en) 2002-05-08
WO2001012175A8 (en) 2001-05-10
HK1047691B (zh) 2006-05-12
MXPA02001569A (es) 2002-07-02
US20040029869A1 (en) 2004-02-12
HK1047691A1 (en) 2003-03-07
US6395788B1 (en) 2002-05-28
DE60021266D1 (de) 2005-08-18
ZA200200852B (en) 2003-07-30
GB0202908D0 (en) 2002-03-27
GB2368522A8 (en) 2002-06-13
IL147777A0 (en) 2002-08-14
WO2001012175A1 (en) 2001-02-22
ATE299369T1 (de) 2005-07-15
GB2368522A (en) 2002-05-08
EP1202722B1 (en) 2005-07-13
ES2192156B1 (es) 2005-02-16
CA2380432A1 (en) 2001-02-22
AU6635400A (en) 2001-03-13
JP2003506484A (ja) 2003-02-18
US20010046988A1 (en) 2001-11-29
NZ516749A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
ES2192156B1 (es) Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina.
AR025111A1 (es) Metodos y composiciones para tratar trastornos de ansiedad generalizada
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DK1742624T3 (da) Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
DK1587506T3 (da) Administration af capsaicinoider
CO5700791A2 (es) Metodos para tratar enfermedades relacionadas con interleukin-6
EA200501867A1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
ATE423553T1 (de) Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
AR039633A2 (es) Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
AR021946A1 (es) Composiciones que contienen feniramina y metodo para el tratamiento de las respuestas alergicas
SE9701161D0 (sv) New use I
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
BR0313665A (pt) Utilização de bupropion para o tratamento da sìndrome das pernas inquietas